MicroRNA-based interventions in aberrant cell cycle diseases: Therapeutic strategies for cancers, central nervous system disorders and comorbidities - 23/07/24
Abstract |
Malignant tumors and central nervous system (CNS) disorders are intricately linked to a process known as "aberrant cell cycle re-entry," which plays a critical role in the progression of these diseases. Addressing the dysregulation in cell cycles offers a promising therapeutic approach for cancers and CNS disorders. MicroRNAs (miRNAs) play a crucial role as regulators of gene expression in cell cycle transitions, presenting a promising therapeutic avenue for treating these disorders and their comorbidities. This review consolidates the progress made in the last three years regarding miRNA-based treatments for diseases associated with aberrant cell cycle re-entry. It encompasses exploring fundamental mechanisms and signaling pathways influenced by miRNAs in cancers and CNS disorders, particularly focusing on the therapeutic effects of exosome-derived miRNAs. The review also identifies specific miRNAs implicated in comorbidity of cancers and CNS disorders, discusses the future potential of miRNA reagents in managing cell cycle-related diseases.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Linking miRNAs to cell cycle dysregulation in cancers and CNS disorders. |
• | Highlighting exosome-derived miRNAs in the treatment of cancers and CNS disorders. |
• | Revealing the shared mechanism of miRNAs-based interventions in cancers and CNS disorders. |
• | Identifying specific miRNAs in comorbidity of cancers and CNS disorders. |
• | Discussing the challenges of miRNA reagents in disease management. |
Abbreviations : CNS, MiRNAs, PC, BC, NSCLC, CRC, MECs, HCC, EMT, TBI, ICH, AD, OGD/R, CI/R, MCAO, NSCs, ADSCs, BBB, SAH, CeRNA, Exos, MSCs, BMSCs
Keywords : MicroRNA, Aberrant cell cycle, Cancer, CNS Disorders, Exosome, Signaling pathways
Plan
Vol 177
Article 116979- août 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?